300 related articles for article (PubMed ID: 18580309)
1. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
3. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
5. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
7. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei.
Lintel NJ; Luebker SA; Lele SM; Koepsell SA
Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622
[TBL] [Abstract][Full Text] [Related]
8. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.
Rubisz P; Ciebiera M; Hirnle L; Zgliczyńska M; Łoziński T; Dzięgiel P; Kobierzycki C
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845657
[TBL] [Abstract][Full Text] [Related]
9. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
Liang Y; Zhang X; Chen X; Lü W
Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
[TBL] [Abstract][Full Text] [Related]
12. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors.
Hakverdi S; Güngören A; Yaldiz M; Hakverdi AU; Toprak S
Eur J Gynaecol Oncol; 2011; 32(5):513-5. PubMed ID: 22053664
[TBL] [Abstract][Full Text] [Related]
14. Digital Quantification of Ki-67 and PHH3 in the Classification of Uterine Smooth Muscle Tumors.
Cao CD; Rico-Castillo J; De Cotiis D; Richard SD; Rosenblum NG; Chan JSY
Int J Gynecol Pathol; 2021 Nov; 40(6):549-555. PubMed ID: 33323861
[TBL] [Abstract][Full Text] [Related]
15. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
17. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
18. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
19. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
20. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]